hotspot -WSS

hotspot

author：entertainment 2025-09-05 18:33:22 - browse：7421

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Baltimore teen accused of firing into crowd during block party mass shooting

hotspot

WSS

New definition of a human embryo proposed amid rapid advances

ProMED sees offers of support, but its future remains unclear

Putin woos African leaders at a summit in Russia with promises of expanding trade and other ties

Listen: Racing for gene therapy & a pioneering approval

Russian and Belarusian players banned from a women's tennis tournament in Prague

FDA approves first treatment for ultra

leisure time

hotspot

focus

Anesthesiologist group: stop taking Ozempic before surgery

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

As Maui death toll rises, number of missing remains unclear

Drug repurposing or repositioning? The language matters

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

Medicare proposal to cover medical devices draws a mixed reaction

Living with Hashimoto's and celiac disease, and med school, too

In Memoriam: Notable people who died in 2023

Clinical trials must include more disabled people

explore

The boys, now 6, who are gene therapy’s ‘edge case’ problem

New details revealed about Purdue's marketing of OxyContin

Patient advocates sound warning on FDA proposal on salt intake

Poland's lawmakers approve a divisive law on Russian influence

HCA says smaller share of spending going to labor

The boys, now 6, who are gene therapy’s ‘edge case’ problem

hotspot

hotspot

leisure time

knowledge